Cargando…

The Combination of JAK2V617F Allele Burden and WT1 Expression can Be Helpful in Distinguishing the Subtype of MPN Patients

INTRODUCTION: Classical Philadelphia-negative myeloproliferative neoplasm (MPN) includes Essential Thrombocythemia (ET), Polycythemia Vera (PV) and Primary Myelofibrosis (PMF). The JAK2V617F mutation is part of the major criteria for diagnosis of MPN. WT1 is reported to be highly overexpressed in mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Sanyun, Luo, Ping, Rouzi, Tuerxunayi, Yu, Yalan, Xiong, Bei, Wang, Yingying, Zuo, Xuelan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10009047/ https://www.ncbi.nlm.nih.gov/pubmed/36895113 http://dx.doi.org/10.1177/10732748231163648

Ejemplares similares

Does increasing the JAK2V617F assay sensitivity allow to identify more patients with MPN?
por: Kouroupi, E, et al.
Publicado: (2012)

JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden
por: Ferdowsi, Shirin, et al.
Publicado: (2016)

JAK2(V617F) allele burden in polycythemia vera: burden of proof
por: Moliterno, Alison R., et al.
Publicado: (2023)

Anti-inflammatory treatment in MPN: targeting TNFR1 and TNFR2 in JAK2-V617F–induced disease
por: Müller, Peter, et al.
Publicado: (2021)

Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN)
por: Zulkeflee, Razan Hayati, et al.
Publicado: (2021)

S208: RELEVANCE OF DORMANT CANCER STEM CELLS IN DISEASE PROPAGATION AND THERAPY RESISTANCEIN JAK2V617F-DRIVEN MPN.
por: Ghezzi, Ian, et al.
Publicado: (2023)

Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2015)

Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden
por: Lee, A-Jin, et al.
Publicado: (2021)

The Burden of JAK2V617F Mutated Allele in Turkish Patients With Myeloproliferative Neoplasms
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2015)

The Unfolded Protein Response Is a Major Driver of LCN2 Expression in BCR–ABL- and JAK2V617F-Positive MPN
por: Tillmann, Stefan, et al.
Publicado: (2021)

Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative Neoplasms
por: Yönal-Hindilerden, İpek, et al.
Publicado: (2023)

P1045: IS JAK2V617F BUT NOT CALR AS DRIVER MUTATION ENOUGH BY ITSELF IN THE PATHOGENESIS OF UNUSUAL TYPE VENOUS THROMBOSIS IN MPN PATIENTS?
por: Morsia, E., et al.
Publicado: (2022)

P980: JAK2V617F-DEPENDENT DOWN REGULATION OF SHP1 EXPRESSION PARTICIPATES IN THE SELECTION OF MPN CELLS IN THE PRESENCE OF TGFΒ
por: Aoun, C., et al.
Publicado: (2022)

PB2192: JAK2 V617F ALLELE BURDEN AND THROMBOTIC EVENTS IN PATIENTS WITH JAK2 V617F POSITIVE POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA AT HIGH RISK OF THROMBOSIS
por: Hwang, Yun Hui, et al.
Publicado: (2023)

Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors
por: Cattaneo, Daniele, et al.
Publicado: (2021)

P1029: JAK2-CHIP IS ASSOCIATED WITH SIMILAR RISK OF CARDIOVASCULAR DISEASE AS JAK2-MPN
por: Grevet, Jeremy, et al.
Publicado: (2023)

The relevance of a low JAK2(V617F) allele burden in clinical practice: a monocentric study
por: Perricone, Margherita, et al.
Publicado: (2017)

Relationship of JAK2 (V617F) Allelic Burden with Clinico-Haematological Manifestations of Philadelphia-Negative Myeloproliferative Neoplasms
por: Yow, Ka Shing, et al.
Publicado: (2020)

JAK2 Exon 14 Skipping in Patients with Primary Myelofibrosis: A Minor Splice Variant Modulated by the JAK2-V617F Allele Burden
por: Catarsi, Paolo, et al.
Publicado: (2015)

ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden
por: Wang, Yu-Hung, et al.
Publicado: (2020)

The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia Chromosome-Negative Myeloproliferative Neoplasm
por: Park, Sang Hyuk, et al.
Publicado: (2013)

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study
por: Vannucchi, Alessandro Maria, et al.
Publicado: (2017)

Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values
por: Silver, Richard T., et al.
Publicado: (2019)

Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera
por: Bjørn, M.E., et al.
Publicado: (2014)

JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation
por: Pandey, Garima, et al.
Publicado: (2022)

Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients
por: Palmer, Jeanne M., et al.
Publicado: (2020)

Influence of JAK2V617F allele burden on clinical phenotype of polycythemia vera patients: A study from India
por: Sazawal, Sudha, et al.
Publicado: (2019)

The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells
por: Mazzacurati, Lucia, et al.
Publicado: (2015)

Allelic Expression Imbalance of JAK2 V617F Mutation in BCR-ABL Negative Myeloproliferative Neoplasms
por: Kim, Hye-Ran, et al.
Publicado: (2013)

Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2 V617F mutant allele detection
por: Zapparoli, Giada V, et al.
Publicado: (2013)

Loss of wild-type Jak2 allele enhances myeloid cell expansion and accelerates myelofibrosis in Jak2V617F knock-in mice
por: Akada, Hajime, et al.
Publicado: (2014)

Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis
por: Tognon, Raquel, et al.
Publicado: (2012)

A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs
por: Link-Lenczowska, Dorota, et al.
Publicado: (2018)

A Comparison of Bone Marrow Morphology and Peripheral Blood Findings in Low and High Level JAK2 V617F Allele Burden
por: Babarović, Emina, et al.
Publicado: (2023)

A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms
por: Fantasia, Francesca, et al.
Publicado: (2013)

JAK2V617F-Positive Endothelial Cells Induce Apoptosis and Release JAK2V617F-Positive Microparticles
por: Hekimoğlu, Hilal, et al.
Publicado: (2022)

Low JAK2 V617F Allele Burden in Ph-Negative Chronic Myeloproliferative Neoplasms Is Associated with Additional CALR or MPL Gene Mutations
por: Makarik, Tatiana V., et al.
Publicado: (2021)

PB2176: MRNA OF MPL AND JAK2 GENES IN PLATELETS IS ASSOCIATED WITH THEIR ASPIRIN RESISTANCE IN MPN PATIENTS
por: Stolyar, Marina, et al.
Publicado: (2023)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET)
por: Zhao, Shixiang, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5ah6780mhj4nf448ffgan3fmit